MCD
MCID: MLT113
MIFTS: 46

Multicentric Castleman Disease (MCD)

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 12 52 15
Plasmablastic Multicentric Castleman Disease 12 52
Multicentric Giant Lymph Node Hyperplasia 12 52
Multi-Centric Castleman's Disease 43 71
Pmcd 12 52
Mcd 12 52
Human Herpesvirus-8-Negative Multicentric Castleman Disease 58
Multicentric Plasma Cell Variant of Castleman's Disease 52
Hhv-8-Negative Multicentric Castleman Disease 58
Idiopathic Multicentric Castleman's Disease 52
Idiopathic Multicentric Castleman Disease 58

Classifications:



External Ids:

Disease Ontology 12 DOID:0111152
MeSH 43 C537372
NCIt 49 C27855
Orphanet 58 ORPHA570431
UMLS 71 C1334815

Summaries for Multicentric Castleman Disease

NIH Rare Diseases : 52 Multicentric Castleman disease (MCD) is a rare disease that affects the lymph nodes and related tissues . It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes (as opposed to unicentric Castleman disease , which involves a single lymph node or single region of lymph nodes). The signs and symptoms of MCD are often nonspecific, and are mild in some people but life-threatening in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. The disease is diagnosed based on the symptoms present, laboratory test results, imaging studies, and results of a biopsy of the lymph nodes which shows specific features when studied under the microscope. In some cases, MCD is caused by human herpesvirus-8 (HHV-8) and is referred to as HHV-8-associated MCD. In other cases, the cause is not known and it is referred to as HHV-8 negative MCD, or idiopathic MCD (iMCD). Treatment of MCD is challenging, and treatment options and outcomes depend on the type and severity in each person.

MalaCards based summary : Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to castleman disease and exanthem, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are PAK Pathway and Allograft rejection. The drugs Sirolimus and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and b cells, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 467)
# Related Disease Score Top Affiliating Genes
1 castleman disease 32.0 PAX5 KRT15 IL6 IL5 IL10 IFNG
2 exanthem 31.1 IL6 IL10 F3 CRP
3 plasma cell neoplasm 30.9 PAX5 IL6 BCL6
4 thrombocytosis 30.7 IL6 F3 CRP
5 bacterial sepsis 30.7 IL6 IL10 CRP
6 peritonitis 30.6 IL6 IL10 IFNG CRP
7 plasmablastic lymphoma 30.6 BCL6 ABCB1
8 pericardial effusion 30.6 IL6 F3 CRP
9 thrombocytopenia 30.5 PAX5 IL6 IL10 IFNG F3 CRP
10 herpes zoster 30.5 IL10 IFNG CRP
11 severe acute respiratory syndrome 30.5 IL6 IL10 IFNG CRP
12 purpura 30.5 IL6 IL10 F3 CRP
13 cellulitis 30.4 IL6 IL5 IL10 CRP
14 respiratory failure 30.3 IL6 IL5 IL10 F3 CRP
15 collagen disease 30.3 IL6 IL10 CRP CFHR2
16 plasmacytoma 30.3 PAX5 IL6 IGH
17 mikulicz disease 30.3 IL5 IL21 IL10 CRP
18 tetanus 30.2 IL6 IL5 IL10 IFNG CRP
19 lymphoma, non-hodgkin, familial 30.1 PAX5 IL6 IL10 IGH CD2 BCL6
20 immune deficiency disease 30.1 IL6 IL10 IFNG CFHR2 CCL4 BCL6
21 pancytopenia 30.1 IL6 IFNG CRP CD2
22 urticaria 30.1 IL6 IL5 CRP
23 common variable immunodeficiency 29.9 IL6 IL5 IL21 IL10 IFNG
24 lung disease 29.8 IL6 IL5 IL10 IFNG F3 CRP
25 autoimmune disease 29.8 IL6 IL5 IL21 IL10 IFNG CRP
26 myeloma, multiple 29.4 PAX5 IL6 IL10 IFNG CRP CD2
27 systemic lupus erythematosus 28.9 IL6 IL5 IL21 IL10 IFNG F3
28 hhv-8-associated multicentric castleman disease 12.7
29 metaphyseal chondrodysplasia, schmid type 12.2
30 malonyl-coa decarboxylase deficiency 12.2
31 macular dystrophy, corneal 12.2
32 multiple carboxylase deficiency 12.1
33 holocarboxylase synthetase deficiency 11.9
34 kaposi sarcoma 11.8
35 human herpesvirus 8 11.8
36 biotinidase deficiency 11.8
37 unicentric castleman disease 11.8
38 focal segmental glomerulosclerosis 11.6
39 c1q nephropathy 11.3
40 corneal dystrophy, meesmann, 1 11.2
41 metaphyseal dysplasia, spahr type 11.2
42 cortical malformations, occipital 11.2
43 microlissencephaly 11.1
44 lymphoproliferative syndrome 10.8
45 cold agglutinin disease 10.6 IL6 CRP
46 prosthetic joint infection 10.6 IL6 CRP
47 nodular lymphocyte predominant hodgkin lymphoma 10.6 PAX5 BCL6
48 cardiogenic shock 10.6 IL6 CRP
49 cryopyrin-associated periodic syndrome 10.6 IL6 CRP
50 acute transverse myelitis 10.6 IL6 IL10

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ABCB1 BCL6 CDON CRP F3 ID1
2 hematopoietic system MP:0005397 10.03 ABCB1 BCL6 CXCL13 F3 F8 ID1
3 immune system MP:0005387 9.97 ABCB1 BCL6 CRP CXCL13 F3 F8
4 digestive/alimentary MP:0005381 9.92 ABCB1 CDON ID1 IFNG IL10 IL5
5 neoplasm MP:0002006 9.5 F3 ID1 IFNG IL10 IL5 IL6
6 respiratory system MP:0005388 9.23 BCL6 CDON F3 ID1 IFNG IL10

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
2
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
3
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
4
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
7
Zidovudine Approved Phase 2 30516-87-1 35370
8
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
9
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
10
Lenograstim Approved, Investigational Phase 2 135968-09-1
11 Antifungal Agents Phase 2
12 Antiemetics Phase 2
13 Gastrointestinal Agents Phase 2
14 Autonomic Agents Phase 2
15 BB 1101 Phase 2
16 Antimetabolites Phase 2
17 Anti-Retroviral Agents Phase 2
18 Reverse Transcriptase Inhibitors Phase 2
19 Antiviral Agents Phase 2
20 Anti-HIV Agents Phase 2
21 Ganciclovir triphosphate Phase 2
22 interferons Phase 2
23 Adjuvants, Immunologic Phase 2
24 Interferon-alpha Phase 2
25 Antibodies, Monoclonal Phase 2
26 Antibodies Phase 2
27 Immunoglobulins Phase 2
28
Methotrexate Approved Phase 1 1959-05-2, 59-05-2 126941
29
Daunorubicin Approved Phase 1 20830-81-3 30323
30
leucovorin Approved Phase 1 58-05-9 6006 143
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
32 Folic Acid Antagonists Phase 1
33 Vitamin B Complex Phase 1
34 Vitamin B9 Phase 1
35 Podophyllotoxin Phase 1 518-28-5
36 Dermatologic Agents Phase 1
37 Folate Phase 1

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
2 A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Recruiting NCT03933904 Phase 2 Sirolimus
3 Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03982771 Phase 2 Bortezomib;Cyclophosphamide;Dexamethason
4 Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
5 Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
6 Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies Recruiting NCT01419561 Phase 2 Zidovudine;Liposomal Doxorubicin;Valganiclovir;Rituximab
7 Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
8 Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) Terminated NCT00127569 Phase 2 Rituximab
9 Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
10 A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda Recruiting NCT03864419 Phase 1 Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide
11 A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
12 A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials Completed NCT00695422
13 Unlock the Cell: Intracellular Inflammatory Pathways and Flow Cytometry Study for Castleman's Disease Recruiting NCT02853968
14 ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease Recruiting NCT02817997
15 Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Recruiting NCT03300830
16 The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research Withdrawn NCT02871050

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

40
Lymph Node, Liver, B Cells, Lung, Spleen, Testes, Bone

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 450)
# Title Authors PMID Year
1
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. 61 52
30181172 2018
2
Idiopathic multicentric Castleman disease: bringing order to chaos. 61
32027863 2020
3
Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study. 61
31211492 2020
4
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. 61
32027862 2020
5
Multicentric Castleman Disease as a Rare Cause of Diffuse Lung Cysts. 61
31914318 2020
6
Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. 61
31829070 2020
7
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. 61
31806686 2020
8
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. 61
31704887 2020
9
KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. 61
31527708 2020
10
HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis. 61
31911409 2020
11
Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab. 61
30486744 2019
12
Induction of Kaposi Sarcoma Associated Herpesvirus-encoded Thymidine Kinase (ORF21) by X-Box Binding Protein-1. 61
31801863 2019
13
Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. 61
31863597 2019
14
Multicentric Castleman disease with TAFRO syndrome and Sjögren's. 61
31893065 2019
15
Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab. 61
31292389 2019
16
Castleman Disease of the Parotid Gland: A Case Report. 61
31837286 2019
17
Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report. 61
31725610 2019
18
Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome). 61
31631463 2019
19
Targeting the mTOR pathway in idiopathic multicentric Castleman disease. 61
31524635 2019
20
The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. 61
31358479 2019
21
In silico insights on IL-6: A Potential target for Multicentric Castleman Disease. 61
31475901 2019
22
Human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. 61
30844089 2019
23
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. 61
31408438 2019
24
Human Herpesvirus-8 Negative Multicentric Castleman Disease in a Patient with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy and Chemotherapy. 61
31523587 2019
25
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. 61
31351487 2019
26
Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab. 61
30989798 2019
27
CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management. 61
31565620 2019
28
The Contribution of Kaposi's Sarcoma-Associated Herpesvirus to Mortality in Hospitalized Human Immunodeficiency Virus-Infected Patients Being Investigated for Tuberculosis in South Africa. 61
31004430 2019
29
miRNAs and their roles in KSHV pathogenesis. 61
30951791 2019
30
Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature. 61
31124053 2019
31
Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? 61
31222819 2019
32
TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient. 61
31453020 2019
33
Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report. 61
31045763 2019
34
Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression. 61
31059555 2019
35
A prospective description of HIV-associated multicentric Castleman disease in Malawi. 61
30442726 2019
36
Spontaneous middle lobe torsion in a patient with multicentric Castleman disease: A case report. 61
30467976 2019
37
Viral, immunologic, and clinical features of primary effusion lymphoma. 61
30782610 2019
38
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. 61
30760451 2019
39
Tufted-angioma-like lesion associated with vascular endothelial growth factor and interleukin-6 in TAFRO syndrome: Is it a common histological feature of multicentric Castleman disease/POEMS syndrome? 61
30632181 2019
40
IgG4-related respiratory disease. 61
30474465 2019
41
IgG4-related disease: what a hematologist needs to know. 61
30705099 2019
42
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders. 61
30610029 2019
43
An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. 61
30642741 2019
44
Unicentric or Multicentric Castleman disease? A case report of a pelvic intraperitoneal mass in a middle aged woman. 61
31565175 2019
45
An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, Who Responded Well to Rituximab Alone. 61
30827270 2019
46
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. 61
29968492 2019
47
A Rare Case of HHV-8 Associated Hemophagocytic Lymphohistiocytosis in a Stable HIV Patient. 61
31183227 2019
48
[Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease]. 61
31597845 2019
49
Live birth after perimortem cesarean delivery in a 36-year-old out-of-hospital cardiac arrest nulliparous woman. 61
30638478 2019
50
AIDS-Associated Malignancies. 61
30523619 2019

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 IL6 IL5 IL21 IL10 CXCL13 CD2
2
Show member pathways
12.54 IL6 IL5 IL21 IL10 IFNG CXCL13
3
Show member pathways
12.47 IL6 IL5 IL21 IL10 IFNG
4 12.42 PAX5 IL10 IFNG CD2 BCL6
5
Show member pathways
12.23 IL6 IL10 CXCL13 CCL4
6
Show member pathways
12.17 IL6 IL5 IL21 IL10 IFNG
7
Show member pathways
11.89 IL6 IL21 IL10 IFNG
8 11.77 IL6 IL21 IL10 IFNG
9 11.71 IL6 IL5 IFNG
10 11.7 IL6 IFNG CCL4
11 11.69 IL5 IL10 IFNG
12 11.65 IL6 IL10 IFNG
13 11.62 IL6 IL5 IL10 IFNG CD2
14 11.56 IL6 IL5 CCL4
15 11.55 IL5 IL10 BCL6
16 11.44 IL6 IL10 IFNG
17 11.42 IL6 IL10 CCL4
18 11.39 IL5 IL10 IFNG
19 11.35 PAX5 IL21 IL10 BCL6
20 11.24 IL6 IL10 IFNG
21 11.14 IL6 IL5 IFNG
22 11.02 IL5 IL10 IFNG
23 10.87 IL6 IL10 IFNG CXCL13 CCL4
24 10.82 IL6 IL5 IL21 IL10 CXCL13 CD2
25 10.72 IL6 IL5 IL10 IFNG

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 IL6 IL5 IL21 IL10 IFNG F8
2 extracellular region GO:0005576 9.4 IL6 IL5 IL21 IL10 IFNG F8

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 IL6 IL21 IFNG
2 humoral immune response GO:0006959 9.63 PAX5 IL6 IFNG
3 cytokine-mediated signaling pathway GO:0019221 9.63 IL6 IL5 IL10 F3 CCL4 BCL6
4 positive regulation of B cell proliferation GO:0030890 9.58 IL5 IL21 BCL6
5 positive regulation of immunoglobulin secretion GO:0051024 9.54 IL6 IL5
6 regulation of angiogenesis GO:0045765 9.54 IL6 ID1 CXCL13
7 positive regulation of MHC class II biosynthetic process GO:0045348 9.52 IL10 IFNG
8 acute-phase response GO:0006953 9.5 IL6 F8 CRP
9 immune response GO:0006955 9.5 IL6 IL5 IL21 IL10 IFNG CXCL13
10 negative regulation of lipid storage GO:0010888 9.49 IL6 CRP
11 germinal center formation GO:0002467 9.48 CXCL13 BCL6
12 type 2 immune response GO:0042092 9.43 IL10 BCL6
13 positive regulation of JAK-STAT cascade GO:0046427 9.43 IL6 IL5 IL10
14 inflammatory response GO:0006954 9.17 IL6 IL5 IL10 CXCL13 CRP CCL4

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 IL6 IL5 IL21 IL10 IFNG CXCL13

Sources for Multicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....